Moderna Set to Report Q4 Results: What to Expect from

Moderna is set to release its financial results for the fourth quarter on February 14, with analysts forecasting a challenging report. The company is expected to report a loss per share of $2.68 on revenue of $942.8 million, marking a significant decline from the same quarter last year. Moderna’s stock has seen a steep decline of around 64% over the past year, driven by waning vaccine demand and ongoing uncertainty in its pipeline.

Expectations for Q4 Results

Moderna’s Q4 results are likely to reflect the difficulties the company is currently facing.

• Analysts expect a loss of $2.68 per share, compared to a profit of $0.55 per share in Q4 2023.
• Revenues are projected to drop by 66%, reaching $942.8 million, further weighed down by reduced vaccine sales.
• The company’s ongoing research and development (R&D) investments are also expected to negatively impact the bottom line.

Despite these challenges, Moderna has managed to meet or exceed analysts’ EPS estimates in seven of the last nine quarters, indicating some resilience.

Analysts’ Views on MRNA Ahead of Q4 Results

Ahead of the earnings announcement, several analysts have lowered their expectations for Moderna.

• Tim Anderson of BofA reduced the firm’s price target to $34 from $41, citing weak vaccine demand and lowering Q4 revenue estimates by 16%.
• Goldman Sachs also downgraded the stock to Hold, cutting its price target from $99 to $51, citing revenue uncertainty and respiratory vaccine concerns.
• Bernstein SocGen Group analyst Courtney Breen trimmed Moderna’s price target to $45 from $55 while maintaining a Market Perform rating.

Options Traders Anticipate a 9.76% Move

Options traders are expecting significant volatility following Moderna’s earnings report.

• According to Options tool, a 9.76% move in either direction is anticipated immediately after the announcement.
• This projection is based on the expected at-the-money straddle of the options closest to expiration after the earnings release.

Is MRNA Stock a Buy?

Moderna’s stock currently holds a Hold consensus rating.

• Based on the last three months, analysts have issued 2 Buy, 10 Hold, and 4 Sell recommendations.
• The average price target for Moderna stock is $48.50, implying a potential upside of 58.83% from current levels.

Important Highlights

• Earnings Expectations: Moderna is projected to report a loss of $2.68 per share and revenues of $942.8 million for Q4.
• Analysts’ Sentiment: Analysts have lowered their price targets, with expectations of continued revenue challenges.
• Options Market: Traders expect a 9.76% move in Moderna’s stock post-earnings.
• Stock Rating: Moderna currently holds a consensus Hold rating with a 58.83% upside potential based on average price targets.